ICOS — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1799816	0.56	13/20
SCHEMBL13315672	0.56	13/20
SCHEMBL1798662	0.55	13/20
SCHEMBL12619377	0.55	13/20
SCHEMBL1800039	0.53	13/20
SCHEMBL1800076	0.53	13/20
SCHEMBL12619404	0.53	13/20
SCHEMBL12619412	0.53	13/20
SCHEMBL13315659	0.53	13/20
SCHEMBL1797470	0.52	13/20
SCHEMBL1800498	0.52	13/20
SCHEMBL12619419	0.52	13/20
SCHEMBL12653018	0.52	13/20
SCHEMBL13376947	0.74	12/20
SCHEMBL3994817	0.63	12/20
SCHEMBL13847917	0.57	12/20
SCHEMBL12653318	0.56	12/20
SCHEMBL12619407	0.55	12/20
SCHEMBL1800497	0.52	12/20
SCHEMBL1796475	1.00	11/20

Clinical trials — most relevant to ICOS by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria	PHASE4	RECRUITING
co Ihibtory Receptor in Preeclampsia	PHASE4	UNKNOWN
Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome	PHASE3	COMPLETED
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)	PHASE3	COMPLETED
Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma	PHASE1/PHASE2	NOT_YET_RECRUITING
a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .	PHASE2	NOT_YET_RECRUITING
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors	PHASE1/PHASE2	COMPLETED
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab	PHASE2	NOT_YET_RECRUITING
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma	PHASE2	ACTIVE_NOT_RECRUITING
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab	PHASE2	ACTIVE_NOT_RECRUITING
AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS	PHASE2	ACTIVE_NOT_RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)	PHASE2	ACTIVE_NOT_RECRUITING
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma	PHASE1/PHASE2	COMPLETED
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease	PHASE2	COMPLETED
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy	PHASE2	COMPLETED
Study of AK119 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer	PHASE1	COMPLETED
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors	PHASE1	COMPLETED
A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer	PHASE1	COMPLETED
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE	PHASE1	RECRUITING
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC	EARLY_PHASE1	UNKNOWN
To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study)	nan	COMPLETED
The Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic Anemia Before and After Tratment	nan	NOT_YET_RECRUITING
Association of Nutrition and T Cell Immune Activity With Disease Progression in Nontuberculous Mycobacterial Pulmonary Disease	nan	NOT_YET_RECRUITING
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial)	nan	ENROLLING_BY_INVITATION
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer	nan	UNKNOWN
The Association of Costimulatory Molecules and PPAR-polymorphisms With Autoimmune Thyroid Disease in Taiwan	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ICOS binder may also engage these)

Protein	Name	Similarity
Q9WVS0	—	0.997	Q9WVS0 →
Q9R1T7	—	0.992	Q9R1T7 →
Q7YR73	—	0.976	Q7YR73 →
Q58DF9	—	0.974	Q58DF9 →
Q07212	—	0.947	Q07212 →
P04216	—	0.945	P04216 →
Q9D806	—	0.939	Q9D806 →
O62643	—	0.936	O62643 →
P23510	—	0.934	P23510 →
P78380	—	0.933	P78380 →
Q9Z0H5	—	0.932	Q9Z0H5 →
Q28110	—	0.931	Q28110 →
Q8C567	—	0.930	Q8C567 →
Q863H3	—	0.929	Q863H3 →
P01830	—	0.929	P01830 →
P01831	—	0.926	P01831 →
O54707	—	0.926	O54707 →
O35778	—	0.925	O35778 →
Q13241	—	0.925	Q13241 →
Q38HS3	—	0.923	Q38HS3 →
Q6GTX8	—	0.923	Q6GTX8 →
Q95JB9	—	0.922	Q95JB9 →
Q9MZK9	—	0.922	Q9MZK9 →
Q8MHY9	—	0.920	Q8MHY9 →
PDCD1LG2	Programmed cell death 1 ligand 2	0.920	landscape →
Q9MZ41	—	0.920	Q9MZ41 →
A0A0E4BZH1	—	0.920	A0A0E4BZH1 →
Q6MG56	—	0.920	Q6MG56 →
A8MVS5	—	0.919	A8MVS5 →
P79391	—	0.919	P79391 →